Treatment for Dermatitis

Phase-Based Estimates
1
Effectiveness
1
Safety
City of Hope Medical Center, Duarte, CA
Dermatitis+2 More
Eligibility
18+
All Sexes
Eligible conditions
Dermatitis

Study Summary

This study is evaluating whether the type of bacteria on skin is different between the affected and unaffected skin in patients who have this treatment-related rash.

See full description

Eligible Conditions

  • Dermatitis
  • Urogenital Neoplasms
  • Neoplasms, Genitourinary

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 6 other outcomes in patients with Dermatitis. Measurement will happen over the course of Up to 1 year.

Up to 1 year
Abundances of certain skin bacteria in lesion
Association between skin microbial diversity and immune checkpoint inhibitor (ICI)-induced dermatitis
Skin microbial diversity
Specific skin bacteria
Tissue and peripheral immune cell phenotypes of ICI-induced dermatitis (I)
Tissue and peripheral immune cell phenotypes of ICI-induced dermatitis (II)
Tissue and peripheral immune cell phenotypes of ICI-induced dermatitis (III)

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

1 Treatment Groups

Control

This trial requires 2 total participants across 1 different treatment groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 1 year for reporting.

Closest Location

City of Hope Medical Center - Duarte, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
People who are treated with any FDA-approved monoclonal antibody that blocks CTLA-4, PD-1, PD-L1, or any combination of those, are more likely to respond to treatment. show original
Patients recommended to undergo skin biopsy due to a clinical diagnosis of ICI-induced dermatitis as part of routine and standard clinical care are eligible
The patient has a poor performance status according to the Eastern Cooperative Oncology Group. show original
Disease that can be measured using the RECIST 1.1 criteria. show original
for the study The patients must be able to sign and date the informed consent form to indicate that they have been informed of all of the pertinent aspects of the study show original
Patients must be age 18 or older

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for dermatitis?

Add answer

Antihistamines may be used for itch, but are of little or no medical value. Topical corticosteroids, such as hydrocortisone cream, are often used for mild to moderate itch, but are typically of limited use for severe itch or skin infection. Antihistamines, topical steroids and antifungal treatments may be used in severe cases of infection. Evidence for their effectiveness is limited, and their benefit may be outweighed by their significant potential for adverse side effects. If anticonvulsants are used, it is primarily due to their long-term benefit, as seizure-related adverse effects are difficult to manage.

Unverified Answer

What are the signs of dermatitis?

Add answer

There are some unique characteristics of dermatitis including the appearance, severity and duration of a rash. These will help in diagnosis and the most appropriate treatment.

Unverified Answer

How many people get dermatitis a year in the United States?

Add answer

The prevalence of AD in this unselected sample of US residents is 2.75%. The number of people with AD appears to be on a continual decline. Recent findings has also demonstrated the need for further epidemiology research to further document the prevalence of AD in different groups and its relation to ethnicity.

Unverified Answer

Can dermatitis be cured?

Add answer

Recent findings indicates that a major goal on the way to better understanding of the pathophysiology of all skin conditions, such as dandruff, is to discover new molecules that could lead to new therapies for skin diseases.

Unverified Answer

What is dermatitis?

Add answer

This form of skin disease is characterized by swollen skin that shows redness, itching and heat. It occurs mainly in infants, toddlers and the elderly. Skin disease is caused by infections such as yeast infection, cold and influenza. In the elderly, it is also related to dry skin which causes loss of water, and may be exacerbated by sun exposure. Topical steroid creams are one way to help dry skin by lowering inflammation. The skin disease 'dermatitis, atopic eczema and allergic contact dermatitis' are common in babies and children. These are all chronic skin diseases. Skin diseases are often caused by environmental contaminants or a genetic component. Many are difficult to treat as a result.

Unverified Answer

What causes dermatitis?

Add answer

The most common risk factors for eliciting dermatitis are exposure and allergies to irritants. Dermatitis can be idiopathic or have a multi-factorial origin; some can be predicted beforehand, and some remain unexplained. Dermatitis is also frequently referred to as 'atopic dermatitis'. It is also strongly related to smoking. Because it is a symptom of a wide range of conditions, its specific pathology is a great source of diagnosis and therapeutic innovation.

Unverified Answer

Have there been other clinical trials involving treatment?

Add answer

It was not uncommon in patients who could participate in the clinical trial. Clinical trials involving treatment are not as straightforward as it first appears [in our experience]. The time that it takes for them to be conducted was very variable; some trials took place when the patients were relatively young, but others were performed in patients 60 years of age and older. However, trials are in their infancy, and there still are many unanswered questions regarding the best way to treat SCCL and whether or not there will be enough research material to develop treatment plans. These questions will be addressed in future clinical trials.

Unverified Answer

What is treatment?

Add answer

The use of the term 'treatment' to describe a procedure without referencing a patient's age, sex, or current state of health is inaccurate and misleading. The use of such terminology is misleading for other reasons.

Unverified Answer

What are the common side effects of treatment?

Add answer

The most frequent side effects experienced were acneic in patients who received etanogest. This finding suggests that the treatment schedule should be optimized in such patients.

Unverified Answer

What is the average age someone gets dermatitis?

Add answer

Results from a recent clinical trial suggest that people in their 40s, 50s, and 60s are most often affected, although those 65 years and older also experience significant D.

Unverified Answer

Is treatment typically used in combination with any other treatments?

Add answer

Oral and intraperitoneal chemotherapy were utilized more frequently with the use of any other treatments. A significant proportion of patients treated with other therapies reported no change or symptomatic improvement. These data suggest the need for more intensive studies of the potential of combination treatment.

Unverified Answer

What is the latest research for dermatitis?

Add answer

Dermatitis is common. Many of the conditions that cause this disease no longer require a diagnosis in a dermatology consultation. Therefore, the diagnostic tests are a challenge for those dermatologists who will become responsible care providers for patients with an increasing number of diagnoses. [Dermatology (Nam Woon Chung, Michael H. Brown, Keith J. Zivonakis, Howard G. Wolansky, Robert M. Stern, James G. B. Crooks, Charles L. Pfeiffer, David L. Ruzin, Steven R. Korshed, John M. Sargeant, James O. Staudt, Anthony J. Zeiger, Jeffrey M. Gorman, Kenneth L.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Dermatitis by sharing your contact details with the study coordinator.